Latest Conference Articles

Azacitidine plus venetoclax and ivosidenib produced robust responses and induced high rates of MRD negativity in IDH1-mutated newly diagnosed AML.

The in vivo CAR T-cell therapy KLN-1010 produced deep MRD-negative responses in relapsed/refractory multiple myeloma.

Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.

Sonrotoclax plus zanubrutinib drove durable remissions across IGHV-mutated and del(17p)/TP53 CLL subgroups in an updated phase 1/1b analysis.

Joshua Richter, MD, previews some of the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress.

Oncology experts provide commentary on the meeting's biggest and most impactful presentations across the GI cancer continuum.

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

Experts share the key myeloproliferative neoplasm and acute myeloid leukemia presentations they’re anticipating at the 2026 EHA Congress.

Breast cancer data from ASCO 2026 confirm the clinical benefits of several investigational treatment approaches across disease subtypes.

Experts delineate the biggest presentations they are looking forward to being presented at the 2026 EHA Congress.

First-line zanubrutinib improved real-world treatment duration, time to next treatment, and survival in older chronic lymphocytic leukemia.

Varegacestat reduced the risk of disease progression or death by 84% vs placebo in progressing desmoid tumors.

Experts outline the key multiple myeloma presentations they are anticipating at the 2026 EHA Congress.

Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.

Dato-DXd led to benefits in terms of TFST, PFS2, and TSST vs chemotherapy in frontline TNBC.

Post-surgery ctDNA status was prognostic for distant recurrence in early TNBC, and the prognostic value of ctDNA status per WGS outperformed pCR status.

Sintilimab plus adjuvant capecitabine did not improve 2-year PFS outcomes vs capecitabine alone in NPC with suboptimal response to induction chemotherapy.

First-line asandeutertinib improved intracranial iORR and IPFS vs osimertinib in EGFR-mutated NSCLC with brain metastases.

Selinexor plus ruxolitinib produced higher SVR35 rates than ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

Zanidatamab plus tislelizumab and chemotherapy improved PFS and OS in HER2-positive mGEA regardless of PD-L1 status by TAP score or CPS.

John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.

TALAPRO-3 showed talazoparib plus enzalutamide cut progression or death risk by 52% in HRR-altered mCSPC vs enzalutamide alone.

A switch to camizestrant upon emergence of an ESR1 mutation improved PFS2 in ER-positive, HER2-negative advanced breast cancer.

Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.

PSMAddition subgroup data show lutetium PSMA-617 triplet yields consistent rPFS, PSA, and mCRPC benefits regardless of disease volume or mHSPC status.

Sacituzumab govitecan plus pembrolizumab improved PFS2 and delayed subsequent therapy vs chemo/pembrolizumab in PD-L1+ mTNBC.

Pemigatinib improved PFS as first-line therapy for FGFR2-rearranged cholangiocarcinoma in the phase 3 FIGHT-302 trial.

Prespecified biomarker analyses of ASCENT-03 and ASCENT-04 showed longer PFS with sacituzumab govitecan–based regimens vs comparators in TNBC.

Rilvegostomig plus T-DXd yielded high pCR rates in immune-positive HER2-negative breast cancer.